文献速递肾移植

免疫学低风险肾移植受者避免使用类固醇安全性的随机对照试验

A Randomized Controlled Trial on Safety of Steroid Avoidance in Immunologically Low-Risk Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2021-12-08

SAILOR 研究为 2 年、多中心、开放标签随机对照试验,纳入 222 例免疫学低风险且无糖尿病的肾移植受者,比较避免类固醇方案与他克莫司/吗替麦考酚酯/泼尼松龙维持方案。1 年时移植后糖尿病发生率两组无显著差异(12.4% vs 18.3%,P=0.30),活检证实的排斥反应亦无显著差异(15% vs 13.8%,P=0.85)。2 年时复合终点、肾功能及不良事件两组相当,避免类固醇组 63.9% 的患者在 2 年时仍未使用类固醇。

要点

  • 免疫学低风险肾移植受者避免类固醇方案 1 年移植后糖尿病发生率 12.4% vs 维持类固醇组 18.3%,无显著差异(P=0.30)。
  • 活检证实的排斥反应 15% vs 13.8%,无显著差异(P=0.85)。
  • 2 年复合终点(无急性排斥、移植物丢失和死亡)81% vs 85%,无显著差异(P=0.4)。

核心结论

  • SAILOR 研究为免疫学低风险肾移植受者采用他克莫司/吗替麦考酚酯维持方案时早期避免类固醇在 2 年时的可行性、安全性和有效性提供了进一步证据。

研究设计与样本

  • 2 年、多中心、开放标签随机对照试验,共 222 例患者随机分配至避免类固醇方案组(他克莫司/吗替麦考酚酯/抗胸腺细胞球蛋白诱导,n=113)或维持类固醇方案组(他克莫司/吗替麦考酚酯/泼尼松龙/巴利昔单抗诱导,n=109)。

主要发现

  • 1 年时移植后糖尿病发生率避免类固醇组 12.4% vs 维持类固醇组 18.3%,无显著差异(P=0.30,CI:16.3-4.4)。
  • 1 年时活检证实的排斥反应发生率避免类固醇组 15% vs 维持类固醇组 13.8%,无显著差异(P=0.85)。
  • 2 年时无急性排斥、移植物丢失和死亡的复合终点避免类固醇组 81% vs 维持类固醇组 85%,无显著差异(P=0.4)。
  • 2 年时两组肾功能及不良事件相当。
  • 避免类固醇组 63.9% 的患者在 2 年时仍未使用类固醇。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Steroid-based immunosuppression after transplantation increases the risk of post-transplant diabetes mellitus (PTDM), with adverse effects on patient and graft survival. In the SAILOR study, we investigated the safety and efficacy of complete steroid avoidance in immunologically low-risk kidney recipients without diabetes on the current standard-of-care maintenance regimen with tacrolimus/mycophenolate mofetil (MMF). METHODS: In this 2-year, multicenter, open-label trial, a total of 222 patients were randomized to receive either steroid avoidance protocol (tacrolimus/MMF/antithymocyte globulin [ATG] induction [n = 113]) or steroid maintenance protocol (tacrolimus/MMF/prednisolone/basiliximab-induction [n = 109]). RESULTS: At 1 year, no significant differences were found between steroid avoidance and steroid maintenance arms in the incidence of PTDM, the primary end point (12.4% vs. 18.3%, respectively, P = 0.30, CI: 16.3-4.4), or in overall biopsy-proven rejections (15% vs. 13.8%, respectively, P = 0.85). At 2 years, the composite end point of freedom from acute rejection, graft loss, and death (81% vs. 85%, respectively, P = 0.4), kidney function, or adverse events was comparable between the 2 arms. Moreover, 63.9% of the patients in the steroid avoidance arm remained free from steroids at 2 years. CONCLUSION: The SAILOR study provides further evidence for the feasibility, safety, and efficacy of early steroid-free treatment at 2 years in immunologically low-risk kidney recipients with tacrolimus/MMF maintenance regimen.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ekberg J, Baid-Agrawal S, Jespersen B, et al. A Randomized Controlled Trial on Safety of Steroid Avoidance in Immunologically Low-Risk Kidney Transplant Recipients. Kidney Int Rep. 2021. PMID: 35155865. doi:10.1016/j.ekir.2021.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。